Bailard Inc. Sells 2,132 Shares of Stryker Corporation $SYK

Bailard Inc. lowered its holdings in Stryker Corporation (NYSE:SYK) by 8.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,651 shares of the medical technology company’s stock after selling 2,132 shares during the period. Bailard Inc.’s holdings in Stryker were worth $8,664,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. United Financial Planning Group LLC bought a new position in Stryker in the third quarter valued at $27,000. Strive Asset Management LLC bought a new position in Stryker in the third quarter valued at $30,000. CGC Financial Services LLC bought a new position in Stryker in the fourth quarter valued at $29,000. ANTIPODES PARTNERS Ltd bought a new position in Stryker in the third quarter valued at $34,000. Finally, Copia Wealth Management grew its position in Stryker by 181.6% in the third quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock valued at $40,000 after purchasing an additional 69 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $282.85 on Tuesday. The stock has a market cap of $108.33 billion, a P/E ratio of 32.74, a P/E/G ratio of 1.80 and a beta of 0.80. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a fifty day moving average price of $336.33 and a two-hundred day moving average price of $353.81. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities analysts predict that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is currently 40.74%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on SYK shares. Robert W. Baird set a $385.00 target price on shares of Stryker in a research report on Friday, May 1st. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 4th. Needham & Company LLC decreased their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price target on shares of Stryker in a research note on Friday, May 1st. Finally, Canaccord Genuity Group cut their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.